Second-Line Treatment With Apatinib in Patients with Recurrent or Refractory Melanoma

Source: Docwire News, March 2022

According to Shumin Yuan and colleagues from the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital in Zhengzhou, China, metastatic malignant melanoma is associated with very poor prognosis, partly due to resistance against conventional chemotherapies. The researchers conducted a phase II trial to assess the safety and efficacy of apatinib, an oral anti-angiogenesis inhibitor, in patients with recurrent advanced melanoma. According to their article, published in The Oncologist, reported that “apatinib showed antitumor activity as a second- or above-line therapy in patients with malignant melanoma,” with manageable toxicity.

The single-arm trial enrolled 15 patients with melanoma from one center to receive apatinib 500 mg daily. Patients had received at least one first-line therapy for advanced melanoma and subsequently recurred. The primary measure of the study was progression-free survival, while secondary endpoints included objective response rate (ORR), disease control rate (DCR), and overall survival (OS).